We would like to express our sincere gratitude for your continuous support.
The following is our business overview of the 11th term. |
|
|
Thanks to a remarkable progress of life science based on proteomics and genomics, researches leading to discovery of molecularly targeted drug, therapeutic antibodies and biomarkers as well as establishment of iPS cells have been rapidly promoted.These newly developed researches bring about innovation in the field of medical science and treatment.
The biotech industry develops and supplies various tools and measuring instruments essential for these researches, but competition in the market is increasingly severe to respond to customers' more specific research themes and needs for affordable prices.
Under such circumstances, we have been distributing knockout mice, antibodies, and their related products and services useful for drug discovery and basic researches to laboratories of universities and pharmaceutical companies, while actively promoting licensing business of our own technologies and innovative seeds. |
|
Business Performance of the 11th Term (April 1, 2008 to March 31, 2009)
|
|
|
Sales decreased but gross operating profit increased. Profit structure has been changing. |
|
We have been changing our profit structure to realize steady growthregardless of circumstance. As a result, net sales became 324 million yen.
However, gross operating profit increasedby 14 million yen on a year-to-year comparison to 171 million yen, since weplaced more importance on profitability in receiving orders. |
|
Losses decreased year on year.Ordinary loss successfully declined for five consecutive terms. |
|
Selling, general and administrative expenses decreased by 6 million yen year on year to 795 million yen, since we have made various efforts at cost cutting through streamlining our research and development structure. On the other hand, aiming for the mid- and long-term expansion of business, we actively concluded exclusive marketing agreements with promising overseas reagent manufacturers and invested in future growth opportunities such as development of new antibody reagents.
As a result, operating loss, ordinary loss and net loss for this term decreased on a year-to-year comparison to 624 million yen, 605 million yen and 634 million yen, respectively. |
|
 Aiming for establishing cancer diagnostic methods using antibodies. |
|
We are promoting research and development on new assay systems using antibodies to diagnose various diseases. As for this effort, we concluded a license agreement with a diagnostic reagent manufacturer regarding cancer diagnosis using urine samples in July 2008, and development of diagnostic regents advanced into the next stage.
Furthermore in October 2008, we filed a patent application with National Cancer Center for an antibody against pancreatic cancer marker and its diagnostic application, which was an achievement of the joint research.We and National Cancer Center also started a project to discover new tumor markers in January 2009.
We will continue these efforts to aim for establishing cancer diagnostic methods using antibodies developed by us.
|
|
| We sincerely ask your kind understanding and continued support of our business. |
|
June,2009
TRANSGENIC INC.
|
